Deferasirox治疗铁质积聚的效果如何？

(Deferasirox, Enriga) may cause rash. Generally, the rash will disappear automatically without the need to adjust the dose or stop the medication; if the situation is serious or persistent, the medication should be stopped. The patient's vision or hearing may be affected. It should be taken 30 minutes before meals. It should be taken at the same time every day. Deferasirox (Deferasirox, Enrig) ​​should not be taken with aluminum-containing drugs (such as gastric acid neutralizers). So, how effective is Deferasirox in treating iron buildup?

A multicenter, prospective clinical trial was conducted to evaluate the safety and efficacy of Deferasirox (deferasirox, Enrig) in patients with low- or intermediate-risk-1 myelodysplastic syndrome (MDS).

The study selected patients with serum ferritin ≥1000 μg/L, transfusion dependence and red blood cell transfusions ≥20U to be included. The starting dose of Deferasirox (Deferasirox, Enrig) is 20 mg/kg/d, which can be adjusted up to 40 mg/kg/d.

A total of 176 patients were enrolled in the study, of whom 173 received treatment. 53% of patients completed 12 months of treatment (n = 91) with a 23% decrease in mean serum ferritin, 36.7% completed 2 years of treatment (N = 49), and 36.5% completed 3 years of treatment (N = 33).

The study found that the reduction of serum ferritin was significantly positively correlated with the improvement of ALT (P <0.001). Baseline labile plasma iron (LPI) was elevated in 68 patients (39.3%). After 13 weeks, all patients with abnormal baseline LPI levels returned to normal.

According to the International Working Group's 2006 criteria, 51 patients (28%) had improved hemograms, of which only 7 patients received growth factors or MDS.

During the 3-year study, 138 (79.8%) patients discontinued treatment, 43 (24.8%) of whom discontinued treatment due to adverse events or disease progression, and 23 (13.2%) due to abnormal laboratory test values. The most common drug-related adverse events were gastrointestinal disturbances and increased serum creatinine. Twenty-eight patients died, but none were related to Deferasirox treatment.

The results of this trial show that Deferasirox (Deferasirox, Enrig) can reduce serum ferritin and LPI in transfusion-dependent MDS patients, and some patients' hemogram and liver function can be improved to a certain extent.

The above is the content of the treatment effects of (Deferasirox, Enriga), I hope it can help you!